Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 3Suspended 2Recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 2Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 1Oropharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Lymphoid Interstitial Pneumonia 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Colonic Neoplasms 1Carcinoma 1

Interventions

Specimen Handling 219pembrolizumab 199Magnetic Resonance Spectroscopy 197Carboplatin 173Cisplatin 139Biopsy 133Nivolumab 129Paclitaxel 115Radiotherapy 111Cyclophosphamide 111Gemcitabine 104durvalumab 90Dexamethasone 90atezolizumab 76Radiation 72Rituximab 71Lenalidomide 69Pemetrexed 66Doxorubicin 65Bevacizumab 65Docetaxel 62Ipilimumab 58Etoposide 57olaparib 55Fluorouracil 52venetoclax 50Taxes 50Radiosurgery 50Oxaliplatin 50Prednisone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × (225)Ac-DOTA-c(RGDyK) × 90 days × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05308446 2026-06-03

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

National Cancer Institute (NCI)

Phase 2 Active not recruiting
86 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT01468896 2026-04-29

Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
23 enrolled 11 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡